K. Milligan's research while affiliated with La Jolla Pharmaceutical and other places

What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (7)

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry
Article
  • Nov 2019
Background and Aims Patients with Immune Thrombocytopenia (ITP) may have bleeding because of low platelet counts; many also have reduced quality of life (QoL). Course of therapy can vary by duration and severity of disease but includes steroids and thrombopoietin receptor agonists [TPO-RA]. Both symptoms of ITP and side effects from treatments impa...
Cite
Request full-text
Cite
Request full-text
Quality of life and tumor location in patients with desmoid tumors: Data from the desmoid tumor research foundation natural history study.
Article
  • May 2019
e18291 Background: Desmoid tumors (DTs) are sarcoma, known to invade surrounding tissues, compromising organ function and complications. As few as 5 per 1 million people are diagnosed with DTs annually, which may be an underestimate of the actual affected population due to difficulty in correctly diagnosing the disease. To improve awareness of DTs...
Cite
Request full-text
Cite
Request full-text
Cite
Request full-text
Cite
Request full-text
Cite
Request full-text

Citations

... This could be partially attributed to the fact that the average disease duration from the time of diagnosis to survey completion was 5.3 years, implying that most patients evaluated in this analysis had chronic ITP. It is often speculated that patients with newly diagnosed ITP have higher anxiety levels due to the uncertainty associated with their disease course [23]. ...
Reference: How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
View
... In one study, the time from patient-reported symptom onset to DT diagnosis exceeded one year for 54% of patients. 30 Correctly diagnosing DT is key to optimizing management but, in practice, can prove challenging. Initial evaluation by a multidisciplinary team with expertise in the management of DT, including medical oncologists, radiation oncologists, radiologists, pathologists, surgeons, and geneticists, is recommended. ...
Reference: Evolving strategies for management of desmoid tumor
View